NCT05582499 - Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy | Biotech Hunter

Enrollment

716

Participants

Timeline

Start Date

November 1, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

September 30, 2028

Conditions

Breast NeoplasmBreast CancerBreast TumorsTriple-Negative Breast Cancer (TNBC)HER2-positive Breast CancerHER2-negative Breast CancerHormone Receptor Positive TumorHormone Receptor Negative TumorEarly-stage Breast CancerLocally Advanced Breast Cancer

Interventions

DRUG

Dalpiciclib

an oral cyclin-dependent kinases (CDK) 4/6 inhibitor

DRUG

Pyrotinib

an irreversible dual pan-erbb receptor tyrosine kinase receptor tyrosine kinase (ERBB) inhibitor

DRUG

SHR-A1811

an anti-HER2 antibody-drug conjugate (ADC)

DRUG

SHR-1316

an anti-programmed death ligand 1 (PD-L1) antibody

DRUG

Camrelizumab

an anti-programmed death-1 (PD1) antibody

DRUG

SHR-A1921

Trophoblast cell-surface antigen 2 (TROP2) ADC

DRUG

Pertuzumab

DRUG

Trastuzumab

DRUG

Goserelin

goserelin

DRUG

Letrozole

letrozole

DRUG

Nab paclitaxel

Albumin paclitaxel

DRUG

Carboplatin

DRUG

Epirubicin

DRUG

Cyclophosphamide

DRUG

Fluzoparib

an original poly adenosine diphosphate-ribose polymerase (PARP) inhibitor

DRUG

Apatinib

tyrosine kinase inhibitors

DRUG

Famitinib

tyrosine kinase inhibitors

DRUG

HB1801

Albumin docetaxel

DRUG

LEM

liposome-entrapped mitoxantrone

DRUG

TQB2102

an anti-HER2 ADC

DRUG

Benmelstobart

an anti-PDL1 antibody

DRUG

Anlotinib

an tyrosine kinase inhibitor

DRUG

TQB2868

anti-PD-1/TGF-βRII

DRUG

Ivonescimab

an anti-PD-1/VEGF bispecific antibody

DRUG

JS207

an anti-PD-1/VEGF bispecific antibody

DRUG

JSKN003

an anti-HER2 ADC

DRUG

HRS-4508

an HER2 inhibitor

DRUG

SHR-4602

an anti-HER2 ADC

DRUG

paclitaxel

Trial Locations (1)

200032

RECRUITING

Fudan University Shanghai Cancer Center Shanghai, China, 200032, Shanghai

All Listed Sponsors

lead

Fudan University

OTHER